Ftse Mib
34.315,24
-1,22%
DAX
20.246,37
-0,33%
S&P 500
6.050,61
-0,39%
NASDAQ
20.109,06
-0,32%
Bitcoin
103.675,43
-2,33%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Avidity Biosciences Inc (RNA) Avidity Biosciences Inc (RNA) Notizie

RNA

Avidity Biosciences (RNA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RNA
DataOraFonteTitoloSimboloCompagnia
16/12/202422:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RNAAvidity Biosciences Inc
14/12/202400:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNAAvidity Biosciences Inc
26/11/202416:00PR Newswire (US)Avidity Biosciences to Participate in Upcoming Investor ConferenceNASDAQ:RNAAvidity Biosciences Inc
21/11/202422:05PR Newswire (US)Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RNAAvidity Biosciences Inc
14/11/202415:39Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RNAAvidity Biosciences Inc
13/11/202422:40Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:RNAAvidity Biosciences Inc
12/11/202413:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAAvidity Biosciences Inc
12/11/202413:00PR Newswire (US)Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology InnovationsNASDAQ:RNAAvidity Biosciences Inc
07/11/202422:05PR Newswire (US)Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent HighlightsNASDAQ:RNAAvidity Biosciences Inc
31/10/202414:00PR Newswire (US)Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024NASDAQ:RNAAvidity Biosciences Inc
30/10/202413:00PR Newswire (US)Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular DystrophyNASDAQ:RNAAvidity Biosciences Inc
03/10/202413:00PR Newswire (US)Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)NASDAQ:RNAAvidity Biosciences Inc
05/09/202415:00PR Newswire (US)Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness MonthNASDAQ:RNAAvidity Biosciences Inc
28/08/202415:00PR Newswire (US)Avidity Biosciences to Participate in Upcoming Investor ConferencesNASDAQ:RNAAvidity Biosciences Inc
19/08/202415:00PR Newswire (US)Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:RNAAvidity Biosciences Inc
15/08/202422:43Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RNAAvidity Biosciences Inc
15/08/202402:30PR Newswire (US)Avidity Biosciences Announces Pricing of Upsized Public Offering of Common StockNASDAQ:RNAAvidity Biosciences Inc
09/08/202423:02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RNAAvidity Biosciences Inc
09/08/202422:23Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RNAAvidity Biosciences Inc
09/08/202422:05PR Newswire (US)Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent HighlightsNASDAQ:RNAAvidity Biosciences Inc
09/08/202413:00PR Newswire (US)Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping inNASDAQ:RNAAvidity Biosciences Inc
05/08/202415:00PR Newswire (US)Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal OfficerNASDAQ:RNAAvidity Biosciences Inc
20/06/202415:00PR Newswire (US)Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD DayNASDAQ:RNAAvidity Biosciences Inc
17/06/202422:05PR Newswire (US)Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:RNAAvidity Biosciences Inc
14/06/202402:00PR Newswire (US)Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common StockNASDAQ:RNAAvidity Biosciences Inc
12/06/202422:01PR Newswire (US)Avidity Biosciences, Inc. Announces Proposed Public Offering of Common StockNASDAQ:RNAAvidity Biosciences Inc
12/06/202413:00PR Newswire (US)Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular DystrophyNASDAQ:RNAAvidity Biosciences Inc
29/05/202422:05PR Newswire (US)Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research CongressNASDAQ:RNAAvidity Biosciences Inc
17/05/202400:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RNAAvidity Biosciences Inc
15/05/202415:10Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAAvidity Biosciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RNA

La tua Cronologia

BIT
TIT
Telecom Italia
BIT
ENI
Eni
BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
ENEL
Enel
BIT
STLAM
Stellantis NV
BIT
TITR
Telecom Italia
BIT
RACE
Ferrari NV
BIT
BPE
Bper Banca
BIT
STMMI
ST Microelectronics
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
SPM
Saipem
BIT
BAMI
Banco BPM
BIT
TEN
Tenaris
BIT
PRY
Prysmian
BIT
MONC
Moncler
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network